Results 151 to 160 of about 2,071 (176)
Some of the next articles are maybe not open access.
Canadian Journal of Health Technologies, 2022
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments ...
openaire +2 more sources
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments ...
openaire +2 more sources
Acne Conglobata and Bimekizumab
JAMA DermatologyThis case report describes 2 patients who received off-label bimekizumab for treatment-resistent acne conglobata.
Matiar, Madanchi +3 more
openaire +2 more sources
Bimekizumab (Bimzelx) for Psoriasis
The Medical Letter on Drugs and TherapeuticsThe FDA has approved the injectable interleukin (IL)-17A/17F antagonist bimekizumab-bkzx (Bimzelx – UCB) for treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic treatment or phototherapy. Bimekizumab is the first IL-17A/17F antagonist to be approved in the US.
openaire +2 more sources
An Overview of Bimekizumab for the Treatment of Psoriatic Arthritis: The Evidence so Far
Drug Design, Development and Therapy, 2021Raquel Faria +2 more
exaly